Javascript must be enabled to continue!
Environmental fate and chemistry of raloxifene hydrochloride
View through CrossRef
Abstract
Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) used for the prevention and treatment of osteoporosis in women. Excretion of raloxifene occurs through the feces of patients. Raloxifene has the potential to be discharged into waste treatment systems after therapeutic use. Raloxifene hydrochloride was investigated using a battery of studies designed to describe its physical/chemical characteristics and define its fate in the environment. The mean measured solubility of raloxifene hydrochloride (± standard deviation) was 345.2 ± 15.6 μg/ml, 13.3 ± 0.6 μg/ml, 0.9224 ± 0.015 μg/ml, and 627.4 ± 132.0 μg/ml in aqueous buffers at pH 5, 7, and 9 and in unbuffered water, respectively. Raloxifene exhibited a mean molar absorptivity of 34,000 and a wavelength absorbance maximum at 287 nm for pH 5 and 7 aqueous buffer solutions and 297 nm at pH 9. Mean measured Km values were 516 ± 17, 1,323 ± 91, and 1,556 ± 135 at pH 5, 7, and 9, respectively. After 5 d at 50°C, raloxifene hydrolyzed 8.02, 10.61, and 23.81% in pH 5, 7, and 9 aqueous buffers, respectively. In a 28-d hydrolysis study at 25°C, the calculated first-order hydrolysis rates were 6.92 × 10−4, 1.70 × 10−3, and 7.66 × 10−3/d, and the corresponding half-lives were 1,001, 410, and 90 d in pH 5, 7, and 9 aqueous buffers, respectively. Raloxifene sorbed significantly to sewage treatment solids with Freundlich isotherm adsorption coefficients K between 2,000 and 3,000. Raloxifene degraded rapidly in the presence of sewage solids. In a system containing 0.470 g/L sludge solids, the raloxifene biodegradation rate and half-life were 0.0966/h and 7.17 h, respectively. In a 28-d aerobic—aquatic biodegradation study containing 30 mg/L sludge solids, the raloxifene biodegradation rate and half-life were 0.0188/d and 37 d, respectively. Given the fate and behavior of raloxifene in these studies, it is anticipated that raloxifene would rapidly dissipate in the environment.
Oxford University Press (OUP)
Title: Environmental fate and chemistry of raloxifene hydrochloride
Description:
Abstract
Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) used for the prevention and treatment of osteoporosis in women.
Excretion of raloxifene occurs through the feces of patients.
Raloxifene has the potential to be discharged into waste treatment systems after therapeutic use.
Raloxifene hydrochloride was investigated using a battery of studies designed to describe its physical/chemical characteristics and define its fate in the environment.
The mean measured solubility of raloxifene hydrochloride (± standard deviation) was 345.
2 ± 15.
6 μg/ml, 13.
3 ± 0.
6 μg/ml, 0.
9224 ± 0.
015 μg/ml, and 627.
4 ± 132.
0 μg/ml in aqueous buffers at pH 5, 7, and 9 and in unbuffered water, respectively.
Raloxifene exhibited a mean molar absorptivity of 34,000 and a wavelength absorbance maximum at 287 nm for pH 5 and 7 aqueous buffer solutions and 297 nm at pH 9.
Mean measured Km values were 516 ± 17, 1,323 ± 91, and 1,556 ± 135 at pH 5, 7, and 9, respectively.
After 5 d at 50°C, raloxifene hydrolyzed 8.
02, 10.
61, and 23.
81% in pH 5, 7, and 9 aqueous buffers, respectively.
In a 28-d hydrolysis study at 25°C, the calculated first-order hydrolysis rates were 6.
92 × 10−4, 1.
70 × 10−3, and 7.
66 × 10−3/d, and the corresponding half-lives were 1,001, 410, and 90 d in pH 5, 7, and 9 aqueous buffers, respectively.
Raloxifene sorbed significantly to sewage treatment solids with Freundlich isotherm adsorption coefficients K between 2,000 and 3,000.
Raloxifene degraded rapidly in the presence of sewage solids.
In a system containing 0.
470 g/L sludge solids, the raloxifene biodegradation rate and half-life were 0.
0966/h and 7.
17 h, respectively.
In a 28-d aerobic—aquatic biodegradation study containing 30 mg/L sludge solids, the raloxifene biodegradation rate and half-life were 0.
0188/d and 37 d, respectively.
Given the fate and behavior of raloxifene in these studies, it is anticipated that raloxifene would rapidly dissipate in the environment.
Related Results
Effects of Raloxifene on Fracture Risk in Postmenopausal Women: The Raloxifene Use for The Heart Trial
Effects of Raloxifene on Fracture Risk in Postmenopausal Women: The Raloxifene Use for The Heart Trial
Abstract
Using data from a randomized placebo-controlled trial of 10,101 postmenopausal women not selected on the basis of osteoporosis, we examined whether the effe...
Cardiovascular Effects of Raloxifene Hydrochloride
Cardiovascular Effects of Raloxifene Hydrochloride
ABSTRACTRaloxifene hydrochloride binds to the estrogen receptor and shows tissue‐selective effects; thus, it belongs to a class of drugs recently described asselective estrogen rec...
Abstract 4598: GP130 as a novel therapeutic target in il-6-dependent cancers
Abstract 4598: GP130 as a novel therapeutic target in il-6-dependent cancers
Abstract
The IL-6/GP130 signaling pathway is critical for the survival and progression of cancer cells of multiple cancer types. We report here the new discovery of ...
First Report of Erythema Multiforme Minor Caused by Raloxifene Hydrochloride
First Report of Erythema Multiforme Minor Caused by Raloxifene Hydrochloride
Raloxifene is a drug used in postmenopausal women with osteoporosis. Although hot flashes are known side effects of raloxifene, to the best of our knowledge, erythema multiforme (E...
The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women
The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women
AbstractThe actual role of Bax protein as a prognostic biomarker that predicts response to therapy remains unclear. The objective of this study was to evaluate the effect of raloxi...
Raloxifene supports early fracture healing more than estrogen in ovariectomized rats
Raloxifene supports early fracture healing more than estrogen in ovariectomized rats
Summary
Objectives: Most people suffering from osteoporosis are undiagnosed: the first osteopenic fracture strikes an untreated organism. Therefore implant fixation often...
Tratamento da osteoporose em Portugal: tendência e variação geográfica.
Tratamento da osteoporose em Portugal: tendência e variação geográfica.
The drugs available in the Portuguese market, for the treatment of osteoporosis, have different mechanisms of action, efficacy, indications, safety profile, and cost, which may inf...
STABILITY INDICATING HPLC METHOD FOR DETERMINATION OF VILAZODONE HYDROCHLORIDE
STABILITY INDICATING HPLC METHOD FOR DETERMINATION OF VILAZODONE HYDROCHLORIDE
Objective: The aim and objective of this study was to develop and validate Stability Indicating HPLC method for determination of Vilazodone Hydrochloride.Methods: The method was ca...

